Media.Player

Mutant mice comprising a mutated type II procollagen alpha-1

总结

This invention relates to the production of dual models of Congenital Heart Defects and Hypertrophic Cardiomyopathy with the use of mice which are genetically modified by transgenic (gene-knockout) techniques. The present invention produces knockout mice that show multiple cardiovascular malformations which will serve as a model of cardiovascular diseases for the screening of potential drugs against ventricular remodeling, malignant arrhythmias, primary pulmonary hypertension, and degenerative valvular diseases, and congenital heart disease.

附加资料

Patent Number: US7645917B2
Application Number: US2005187160A
Inventor: Cheah, Kathryn Song-Eng | Zhang, Janet Chyng-Jiau Lin
Priority Date: 26 Jul 2004
Priority Number: US7645917B2
Application Date: 22 Jul 2005
Publication Date: 12 Jan 2010
IPC Current: A01K0067027 | C12N001500 | G01N003300
US Class: 800018 | 800003 | 800021
Assignee Applicant: The University of Hong Kong
Title: Mutant mice comprising a mutated type II procollagen alpha-1
Usefulness: Mutant mice comprising a mutated type II procollagen alpha-1
Summary: (M1) is useful for producing mutant Col2A-1 transgenic mouse. (M2) is useful for producing a mutant mouse. (I) is useful for screening agents for treatment of a selected cardiac disorder, where the selected cardiac disorders include sudden cardiac death, cardiomegaly, cardiomyocyte, hypertrophy, cellular disarray, pulmonary hypertension with right ventricular hypertrophy, and valvular fibrosis (all claimed). (M1) is useful for screening potential drugs against ventricular remodeling, malignant arrhythmias, and congenital heart disease.
Novelty: Producing mutant procollagen IIA (Col2A-1) transgenic mouse, by introducing selected mouse embryonic stem cells having mutant Col2A-1 transgene into mouse blastocysts, and crossing chimeric founder transgenic mouse with wild-type mouse

主要类别

生物医学

细分类别

DNA /基因工程

申请号码

US2005187160A

国家/地区

香港